Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07255846
PHASE1

A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia

Sponsor: Terremoto Biosciences Inc.

View on ClinicalTrials.gov

Summary

This is a Phase 1a/1b, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of TER-1754 (a novel AKT1 inhibitor) in patients with HHT.

Official title: A Phase 1 Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

90

Start Date

2025-12-15

Completion Date

2028-03

Last Updated

2026-01-08

Healthy Volunteers

No

Interventions

DRUG

TER-1754

QD or BID, orally in 28-day cycles

DRUG

Placebo

Number of tablets will be confirmed post Phase 1a

DRUG

TER-1754

Phase 1b dose to be determined post Phase 1a

Locations (1)

Innovative Hematology, Inc.

Indianapolis, Indiana, United States